FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 75 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... February 25, 2026 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods April 27, 2020 Load more HOT NEWS FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... New on NCI’s Websites for December 2020 Immunotherapy approved for some people with advanced melanoma in England FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute...
